Payment overview · 2025
General Payments
$526.17
29 reported records · 5 companies
Healthcare provider profile · identity verified
Waref Azmeh, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BATON ROUGE, LA · NPI 1467408492
Verified facts
What the public records show
CMS Open Payments records show Waref Azmeh, MD received $526.17 in general payments during 2025 across 29 reported records.
ViiV Healthcare Company accounted for 57.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arikayce, Cabenuva, Mytesi, Pifeltro, Rukobia.
Insmed, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Arikayce as an associated drug or biological on 32500 records involving 8305 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Arikayce by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported DELSTRIGO as an associated drug or biological on 864 records involving 608 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Delstrigo by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ISENTRESS as an associated drug or biological on 37 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 171 claims for Isentress by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PIFELTRO as an associated drug or biological on 7921 records involving 2912 distinct recipient NPIs. Public Medicare Part D data also shows 230 claims for Pifeltro by this doctor in 2024.
Napo Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Mytesi as an associated drug or biological on 1178 records involving 562 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Mytesi by this doctor in 2024.
ViiV Healthcare Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CABENUVA as an associated drug or biological on 13941 records involving 3305 distinct recipient NPIs. Public Medicare Part D data also shows 157 claims for Cabenuva by this doctor in 2024.
ViiV Healthcare Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RUKOBIA as an associated drug or biological on 3367 records involving 1303 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rukobia by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $301.40 | 57.3% | 20 | 2025 |
| Theratechnologies Inc. | Unresolved — no canonical attribution shown | $84.03 | 16.0% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $65.33 | 12.4% | 3 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $47.54 | 9.0% | 2 | 2025 |
| Napo Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $27.87 | 5.3% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $526.17 | 29 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CABENUVA Normalized: cabenuva |
Drug | ViiV Healthcare Company | $281.88 | 19 | 2025 |
Source payment records
|
|||||
| EGRIFTA Normalized: egrifta |
Drug | Theratechnologies Inc. | $84.03 | 2 | 2025 |
Source payment records
|
|||||
| TROGARZO Normalized: trogarzo |
Drug | Theratechnologies Inc. | $84.03 | 2 | 2025 |
Source payment records
|
|||||
| PIFELTRO Normalized: pifeltro |
Drug | Merck Sharp & Dohme LLC | $65.33 | 3 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $47.54 | 2 | 2025 |
Source payment records
|
|||||
| Mytesi Normalized: mytesi |
Drug | Napo Pharmaceuticals Inc | $27.87 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $23.59 | 1 | 2025 |
Source payment records
|
|||||
| RUKOBIA Normalized: rukobia |
Drug | ViiV Healthcare Company | $19.52 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Arikayce arikayce |
2025 | Arikayce | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| CABENUVA cabenuva |
2025 | Cabenuva | 2024 | 157 | exact normalized | Medicare Part D |
| Mytesi mytesi |
2025 | Mytesi | 2024 | 54 | exact normalized | Medicare Part D |
| PIFELTRO pifeltro |
2025 | Pifeltro | 2024 | 230 | exact normalized | Medicare Part D |
| RUKOBIA rukobia |
2025 | Rukobia | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Insmed, Inc. Exact reporting entity; no affiliate inference |
2025 | Arikayce open payments reported associated product |
CMS Open Payments — General Payments 32500 supporting records · 8305 recipient NPIs · example record 1186254431 |
Arikayce · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | DELSTRIGO open payments reported associated product |
CMS Open Payments — General Payments 864 supporting records · 608 recipient NPIs · example record 1237993240 |
Delstrigo · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | ISENTRESS open payments reported associated product |
CMS Open Payments — General Payments 37 supporting records · 24 recipient NPIs · example record 1238003286 |
Isentress · 2024 Exact normalized brand match · 1 Part D row |
171 | 16 |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | PIFELTRO open payments reported associated product |
CMS Open Payments — General Payments 7921 supporting records · 2912 recipient NPIs · example record 1237992198 |
Pifeltro · 2024 Exact normalized brand match · 1 Part D row |
230 | 24 |
| Napo Pharmaceuticals Inc Exact reporting entity; no affiliate inference |
2025 | Mytesi open payments reported associated product |
CMS Open Payments — General Payments 1178 supporting records · 562 recipient NPIs · example record 1223618503 |
Mytesi · 2024 Exact normalized brand match · 1 Part D row |
54 | 11 |
| ViiV Healthcare Company Exact reporting entity; no affiliate inference |
2025 | CABENUVA open payments reported associated product |
CMS Open Payments — General Payments 13941 supporting records · 3305 recipient NPIs · example record 1189508908 |
Cabenuva · 2024 Exact normalized brand match · 1 Part D row |
157 | 28 |
| ViiV Healthcare Company Exact reporting entity; no affiliate inference |
2025 | RUKOBIA open payments reported associated product |
CMS Open Payments — General Payments 3367 supporting records · 1303 recipient NPIs · example record 1189508926 |
Rukobia · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 698 | 66 |
| Odefsey | Emtricitab/Rilpiviri/Tenof Ala | 450 | 42 |
| Descovy | Emtricitabine/Tenofov Alafenam | 370 | 34 |
| Fluticasone Propionate | Fluticasone Propionate | 357 | 48 |
| Valacyclovir | Valacyclovir Hcl | 348 | 64 |
| Atorvastatin Calcium | Atorvastatin Calcium | 338 | 66 |
| Amlodipine Besylate | Amlodipine Besylate | 337 | 52 |
| Alprazolam | Alprazolam | 330 | 40 |
| Pantoprazole Sodium | Pantoprazole Sodium | 303 | 48 |
| Mounjaro | Tirzepatide | 263 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 234 | 34 |
| Pifeltro | Doravirine | 230 | 24 |
| Ozempic | Semaglutide | 229 | 27 |
| Tadalafil | Tadalafil | 210 | 29 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 207 | 42 |
| Potassium Chloride | Potassium Chloride | 206 | 24 |
| Juluca | Dolutegravir/Rilpivirine | 199 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 197 | 31 |
| Gabapentin | Gabapentin | 194 | 32 |
| Genvoya | Elviteg/Cob/Emtri/Tenof Alafen | 193 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 187 | 30 |
| Furosemide | Furosemide | 187 | 25 |
| Isentress | Raltegravir Potassium | 171 | 16 |
| Ezetimibe | Ezetimibe | 170 | 32 |
| Zolpidem Tartrate | Zolpidem Tartrate | 160 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 159 | 22 |
| Cabenuva | Cabotegravir/Rilpivirine | 157 | 28 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 152 | 25 |
| Metoprolol Succinate | Metoprolol Succinate | 134 | 26 |
| Levothyroxine Sodium | Levothyroxine Sodium | 129 | 17 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 128 | 18 |
| Metformin Hcl | Metformin Hcl | 127 | 18 |
| Vascepa | Icosapent Ethyl | 124 | 17 |
| Fluconazole | Fluconazole | 119 | 34 |
| Symtuza | Darunavir/Cob/Emtri/Tenof Alaf | 107 | 11 |
| Testosterone | Testosterone | 106 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 102 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 102 | 13 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 99 | 12 |
| Allopurinol | Allopurinol | 97 | 13 |
| Triumeq | Abacavir/Dolutegravir/Lamivudi | 96 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 94 | 15 |
| Ketoconazole | Ketoconazole | 93 | 17 |
| Pregabalin | Pregabalin | 92 | 14 |
| Dutasteride | Dutasteride | 91 | 13 |
| Jardiance | Empagliflozin | 89 | 13 |
| Methylprednisolone | Methylprednisolone | 89 | 59 |
| Bupropion Xl | Bupropion Hcl | 88 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 86 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 85 | 13 |
| Trazodone Hcl | Trazodone Hcl | 84 | 11 |
| Darunavir | Darunavir | 83 | suppressed |
| Lisinopril | Lisinopril | 81 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 79 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 78 | 53 |
| Meloxicam | Meloxicam | 77 | 14 |
| Farxiga | Dapagliflozin Propanediol | 76 | 11 |
| Linzess | Linaclotide | 76 | 15 |
| Nevirapine Er | Nevirapine | 76 | suppressed |
| Carvedilol | Carvedilol | 73 | suppressed |
| Efavirenz-Emtric-Tenofov Disop | Efavirenz/Emtricit/Tenofovr Df | 73 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 73 | 14 |
| Acyclovir | Acyclovir | 72 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 72 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 72 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 72 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 71 | 12 |
| Lorazepam | Lorazepam | 69 | suppressed |
| Famotidine | Famotidine | 65 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 64 | suppressed |
| Amoxicillin | Amoxicillin | 60 | 17 |
| Tramadol Hcl | Tramadol Hcl | 59 | suppressed |
| Estradiol | Estradiol | 58 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 57 | suppressed |
| Prezcobix | Darunavir/Cobicistat | 56 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 56 | suppressed |
| Mytesi | Crofelemer | 54 | 11 |
| Evotaz | Atazanavir Sulfate/Cobicistat | 52 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 52 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 51 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 51 | suppressed |
| Finasteride | Finasteride | 49 | 11 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 48 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 48 | 16 |
| Isentress Hd | Raltegravir Potassium | 48 | suppressed |
| Ritonavir | Ritonavir | 48 | suppressed |
| Lamivudine | Lamivudine | 47 | suppressed |
| Repatha Sureclick | Evolocumab | 47 | suppressed |
| Trulicity | Dulaglutide | 47 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 46 | suppressed |
| Delstrigo | Doravirine/Lamivu/Tenofov Diso | 45 | suppressed |
| Famciclovir | Famciclovir | 45 | suppressed |
| Losartan Potassium | Losartan Potassium | 45 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 44 | suppressed |
| Celecoxib | Celecoxib | 44 | 13 |
| Omeprazole | Omeprazole | 44 | suppressed |
| Dapsone | Dapsone | 43 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 43 | suppressed |
| Lidocaine | Lidocaine | 42 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 42 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 41 | suppressed |
| Edurant | Rilpivirine Hcl | 41 | suppressed |
| Levetiracetam | Levetiracetam | 41 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 41 | suppressed |
| Tivicay | Dolutegravir Sodium | 38 | suppressed |
| Xarelto | Rivaroxaban | 38 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 37 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 37 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 37 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 37 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 37 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 36 | suppressed |
| Januvia | Sitagliptin Phosphate | 36 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 35 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 35 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 35 | suppressed |
| Vemlidy | Tenofovir Alafenamide | 35 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 34 | 14 |
| Azithromycin | Azithromycin | 33 | 15 |
| Spironolactone | Spironolactone | 33 | suppressed |
| Vraylar | Cariprazine Hcl | 33 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 32 | suppressed |
| Ondansetron Odt | Ondansetron | 32 | suppressed |
| Colchicine | Colchicine | 31 | suppressed |
| Efavirenz | Efavirenz | 31 | suppressed |
| Ethambutol Hcl | Ethambutol Hcl | 31 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 31 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 31 | suppressed |
| Nuzyra | Omadacycline Tosylate | 30 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 30 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 24 |
| Fluocinonide | Fluocinonide | 29 | suppressed |
| Ibuprofen | Ibuprofen | 29 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 29 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 29 | suppressed |
| Baclofen | Baclofen | 28 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 28 | suppressed |
| Bicillin L-A | Penicillin G Benzathine | 27 | suppressed |
| Ertapenem | Ertapenem Sodium | 27 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 27 | suppressed |
| Atenolol | Atenolol | 26 | suppressed |
| Cephalexin | Cephalexin | 26 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 26 | 19 |
| Desloratadine | Desloratadine | 26 | suppressed |
| Eliquis | Apixaban | 26 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 26 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 26 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 26 | suppressed |
| Serostim | Somatropin | 26 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Atazanavir Sulfate | Atazanavir Sulfate | 25 | suppressed |
| Egrifta Sv | Tesamorelin Acetate | 25 | suppressed |
| Lopinavir-Ritonavir | Lopinavir/Ritonavir | 25 | suppressed |
| Viracept | Nelfinavir Mesylate | 25 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 24 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 24 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | suppressed |
| Entresto | Sacubitril/Valsartan | 23 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 23 | suppressed |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Amikacin Sulfate | Amikacin Sulfate | 22 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 22 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 22 | suppressed |
| Rukobia | Fostemsavir Tromethamine | 22 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | suppressed |
| Clonazepam | Clonazepam | 21 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 21 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 21 | suppressed |
| Maraviroc | Maraviroc | 21 | suppressed |
| Mirtazapine | Mirtazapine | 21 | suppressed |
| Prednisone | Prednisone | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Valsartan | Valsartan | 21 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 20 | suppressed |
| Lamotrigine | Lamotrigine | 20 | suppressed |
| Linezolid | Linezolid | 20 | suppressed |
| Rybelsus | Semaglutide | 20 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 19 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 19 | suppressed |
| Sunlenca | Lenacapavir Sodium | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 18 | suppressed |
| Abacavir | Abacavir Sulfate | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Levofloxacin | Levofloxacin | 17 | 15 |
| Promethazine Hcl | Promethazine Hcl | 17 | suppressed |
| Selzentry | Maraviroc | 17 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 16 | suppressed |
| Livalo | Pitavastatin Calcium | 16 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 16 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | 11 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 15 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Abacavir-Lamivudine | Abacavir Sulfate/Lamivudine | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Caplyta | Lumateperone Tosylate | 14 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Glyburide | Glyburide | 14 | suppressed |
| Praluent Pen | Alirocumab | 14 | suppressed |
| Prezista | Darunavir | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 13 | 11 |
| Cialis | Tadalafil | 13 | suppressed |
| Dronabinol | Dronabinol | 13 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 13 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Quviviq | Daridorexant Hcl | 13 | suppressed |
| Ramelteon | Ramelteon | 13 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Xanax | Alprazolam | 13 | suppressed |
| Bicalutamide | Bicalutamide | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 12 | suppressed |
| Leucovorin Calcium | Leucovorin Calcium | 12 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Sulfasalazine Dr | Sulfasalazine | 12 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 12 | suppressed |
| Arikayce | Amikacin Liposomal/Neb.Accessr | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Carisoprodol | Carisoprodol | 11 | suppressed |
| Clonidine | Clonidine | 11 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 11 | suppressed |
| Neupogen | Filgrastim | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $526.17 · 29 records | ViiV Healthcare Company | Arikayce, CABENUVA, CAPVAXIVE, EGRIFTA, Mytesi, PIFELTRO, RUKOBIA, TROGARZO | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arikayce play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Insmed, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error